Intel (NASDAQ: INTC ) talks a big game about its future, promising to make its way into nearly every computing device imaginable. Whether it's PCs, tablets, smartphones, or other computing devices, Intel wants its processors to power the future of computing. To date, Intel hasn't been very successful in delivering on its promise, given that the world has embraced mobile computing faster than Intel can keep up with.
For Intel to remain relevant in the world of mobile computing, it needs to deliver a highly efficient yet powerful mobile computing solution that outperforms the sea of ARM Holdings (NASDAQ: ARMH ) designs. Moreover, it should probably get used to the fact that it won't be able to command the premiums it's grown accustomed to in the PC world.
To pull off this foray into mobile computing, Intel is banking on its leading-edge capacity to carry the weight of its ambitions, which bears the lowest unit cost, offers the highest performance, and consumes the lowest power. In other words, after a complete makeover, Intel Atom will hopefully become Intel's knight in shining armor on nearly all computing fronts.
Top Dow Dividend Stocks To Own For 2015: Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).
As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.
Molecular Diagnostic Tests
The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.
The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.
The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.
Companion Diagnostic Services and Other Revenue
! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.
The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.
Advisors' Opinion:- [By Sean Williams]
Preventative treatments
In terms of preventative measures, genetic companies have made big strides over the past couple of decades with regard to disease detection. Myriad Genetics (NASDAQ: MYGN ) , for example, offers the BRACAnalysis genetic test to help determine if patients carry the BRCA1 or BRCA2 gene mutation that's responsible for a majority of hereditary breast and ovarian cancers. In addition to having a higher propensity to developing breast or ovarian cancer, BRCA1 or BRCA2 gene carriers are more susceptible to developing a second primary cancer. This test offered by Myriad gives patients a quick answer as to whether they're a carrier, helping them determine the next best course of action, which can include increased cancer screenings, hormone therapy, or, in Jolie's case, a preventative mastectomy. - [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Myriad Genetics Inc.(MYGN) slid 9.9% to $34 premarket after saying that a Utah court denied its motion for a preliminary injunction against Ambry Genetics’ breast cancer tests. Several companies began selling BRCA genetic tests after the Supreme Court invalidated some of Myriad’s patents last summer. Myriad alleges that Ambry’s testing services infringe various other patent claims.
Top 5 Promising Stocks To Watch For 2014: Publicis Groupe SA (PUB)
Publicis Groupe SA (Publicis Groupe) is a France-based company engaged in the provision of advertising services, specialized agencies and marketing services (SAMS) and media services. Its primary activities include communications, media agency, and digital and healthcare communications. Publicis Groupe offers local and international clients a complete range of advertising services through three global advertising networks: Leo Burnett, Publicis, Saatchi & Saatchi, and two multi-hub networks, Fallon and 49%-owned Bartle Bogle Hegarty. In August 2013, the Company acquired Engauge Marketing LLC. In November 2013, it announced the acquisition of ETO. In November 2013, it acquired majority of shares of Walker Media from M&C Saatchi PLC. In December 2013, Publicis Groupe SA acquired Synergize Digital Pty Ltd. In December 2013, it acquired Verilogue Inc. In January 2014, it acquired Qorvis Communications. Advisors' Opinion:- [By Jonathan Morgan]
European stocks climbed to a six-week high as Publicis (PUB) Groupe SA posted increased profit, London Stock Exchange Group Plc reported higher revenue and fewer Americans than forecast filed jobless-benefit claims.
Top 5 Promising Stocks To Watch For 2014: Discover Financial Services(DFS)
Discover Financial Services, a bank holding company, offers direct banking and payment services in the United States. It operates in two segments, Direct Banking and Payment Services. The Direct Banking segment offers Discover card-branded credit cards to individuals and small businesses that are accepted on the Discover Network. This segment also provides other consumer banking products and services, including personal loans, student loans, and prepaid cards, as well as other consumer lending and deposit products, such as certificates of deposit, money market accounts, online savings accounts, and individual retirement account. The Payment Services segment operates the PULSE network, an automated teller machine, debit, and electronic funds transfer network; the Diners Club International network, a global payments network; and third-party issuing business, which includes credit, debit, and prepaid cards issued on the Discover Network by third parties. The company was found ed in 1986 and is based in Riverwoods, Illinois.
Advisors' Opinion:- [By Jon C. Ogg]
It seems that the market likes JPMorgan exiting one non-core asset class like this. Its shares were up $0.35 at $52.22 in late Thursday trading. Wells Fargo & Co. (NYSE: WFC) was up $0.36 at $41.86 and Discover Financial Services (NYSE: DFS) was up $0.38 at $48.71 in late-day trading on Thursday.
- [By Marc Bastow]
Leading the way was financial services and payment processor Discover Financial (DFS), which put a solid dividend increase into the wallets of its shareholders. Here’s a look at the new dividends being paid out to DFS stock holders, along with improvements from other dividend stocks this week. (Note: All dividend yields are as of April 17.)
- [By Lee Jackson]
Discover Financial Services Inc. (NYSE: DFS) is another play where investors are positive about the credit card business. We recently wrote about credit card companies having success with their customers.�Oppenheimer has a $57 price target for the stock, the same as the consensus target. Shareholders are paid a 1.6% dividend.
- [By Bloomberg]
Alamy More U.S. banks may soon give free FICO credit scores to millions of card customers along with their monthly bills as Discover Financial Services (DFS) extends the offering to all of its cardholders. FICO (FICO), formerly known as Fair Isaac Corp., is negotiating with some of the largest credit-card issuers, Anthony Sprauve, the San Jose, California-based firm's senior consumer-credit specialist, said in a phone interview, declining to identify the banks. Discover, which began providing the scores to some clients in November, will now furnish them to all consumer cardholders, the lender said in an e-mailed statement. 'Jammed Space' on Statements "It really does come down to the technology-implementation challenges," Sprauve said. "You're talking about millions of customers, a tremendous amount of data, and how do you squeeze more data in an already jammed space" on monthly statements, he said. FICO scores are used in lending decisions, such as for issuing credit cards or setting interest rates on home loans, and are the most widely used credit-scoring formula in the U.S. They previously were available at a cost or through online trial subscriptions.
Top 5 Promising Stocks To Watch For 2014: Norsk Hydro ASA (NHY)
Norsk Hydro ASA is a Norway-based company engaged in a number of activities along the aluminum industry�� value chain. The Company is organized into six segments; the Bauxite & Alumina segment includes the Company�� mining activities, sourcing arrangements and alumina commercial operations; the Primary Metal segment consists of aluminum production, re-melting and casting activities; the Metal Markets segment includes sales and distribution activities relating to products from metal plants, metal sourcing and trading activities; the Rolled Products segment comprises operations of the Company�� rolling mills; the Extruded Products segment focuses on delivering solutions to the building and construction, transportation, and engineered products industries and includes aluminum building systems and precision tubing activities, and the Energy segment is responsible for managing the Company�� captive hydropower production and external power sourcing arrangements to the aluminum business. Advisors' Opinion:- [By Corinne Gretler]
Norsk Hydro (NHY) ASA slumped the most in one year after Vale SA sold a stake in the aluminum maker. UniCredit SpA (UCG) and Infineon Technologies AG added at least 1 percent each after posting quarterly profit that beat projections. Henkel AG rose 2.1 percent as third-quarter profit beat analysts��estimates.
No comments:
Post a Comment